# Study of MEDI-547 to Evaluate the Safety, Tolerability, and Biologic Activity of IV Administration in Subjects With Relapsed or Refractory Solid Tumors

> **NCT00796055** · PHASE1 · TERMINATED · sponsor: **MedImmune LLC** · enrollment: 6 (actual)

## Conditions studied

- Cancer

## Interventions

- **DRUG:** MEDI-547

## Key facts

- **NCT ID:** NCT00796055
- **Lead sponsor:** MedImmune LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-08
- **Primary completion:** 2010-02
- **Final completion:** 2010-06
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** MI-CP177 study closed per sponsor decision.
- **Last updated:** 2011-11-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00796055

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00796055, "Study of MEDI-547 to Evaluate the Safety, Tolerability, and Biologic Activity of IV Administration in Subjects With Relapsed or Refractory Solid Tumors". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00796055. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*